Maria Antoniou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Antoniou has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Antreas Afantitis
NovaMechanics Ltd, Nicosia 1070, Cyprus
6 shared publications - Georgia Melagraki
Division of Physical Sciences and Applications, Hellenic Military Academy, Vari 16672, Greece
5 shared publications - Iseult Lynch
School of Geography, Earth & Environmental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
4 shared publications - Konstantinos D. Papavasileiou
Department of ChemoInformatics, Novamechanics Ltd., Nicosia 1070, Cyprus
3 shared publications - Dimitra-Danai Varsou
NovaMechanics MIKE, Piraeus 18545, Greece
2 shared publications - Aikaterini Theodori
Department of ChemInformatics, NovaMechanics MIKE, 18545 Piraeus, Greece
1 shared publication
Latest Publications
- Open Access
- 22 December 2025
- Published by Royal Society of Chemistry (RSC) in Environmental Science: Nano
- Vol. 13 (1) , 621-640
Rigorous data curation, enrichment and meta-analysis enable autoML prediction of plant length responses to nanoparticles powered by the Enalos Cloud platform
A nanoparticle–plant dataset with atomistic descriptors was developed and used to train an optimized XGBoost model to predict nanoparticle effects on plant length without experimental data. Image designed with https://canva.com.
- 22 December 2025
- Published by Royal Society of Chemistry (RSC) in Environmental Science: Nano
- Vol. 13 (1) , 621-640
Open AccessRigorous data curation, enrichment and meta-analysis enable autoML prediction of plant length responses to nanoparticles powered by the Enalos Cloud platform
A nanoparticle–plant dataset with atomistic descriptors was developed and used to train an optimized XGBoost model to predict nanoparticle effects on plant length without experimental data. Image designed with https://canva.com.
- Open Access
- 25 November 2025
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
- Vol. 8 (2) , 646-661
Atom-level descriptors and explainable prediction of iron carbide nanoparticles' cytotoxicity via the Enalos Cloud platform
Iron carbide nanoparticles (ICNPs), a distinct type of magnetic nanostructure, have been proposed as novel candidate therapeutic agents for a wide range of biomedical applications, yet their biocompatibility remains a critical concern for their safe implementation. To mitigate the need for excessive experiments that screen bio-related interactions through conventional pathways, in silico methodologies have been established as cost and time-efficient alternatives. This study presents the development of data-driven workflows for the risk assessment of ICNP-induced cytotoxicity. Two modelling strategies were established: an evidence-based approach relying on experimental features and exposure conditions, and an atomistic-based approach combining attributes that describe NPs at the atomistic scale. While the former methodology struggled to meet the requirements for robust quantitative predictions, the models implemented on the enriched dataset displayed improved accuracy. The resultant Random Forest model fully adheres to the principles outlined by the OECD for the development of quantitative structure–toxicity relationship (QSTR) models. Beyond deciphering the mechanistic influence of individual features, the effect of the selected nanodescriptors was reviewed through Shapley additive values and permutation importance analyses to reveal key input characteristics that drive cell viability predictions. The produced model is disseminated as a free to use web service hosted by the Enalos CHIASMA Cloud Platform (https://www.enaloscloud.novamechanics.com/chiasma/icnp/) and data are publicly available through the NanoPharos database for easy access to the nano-safety community.
- 25 November 2025
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
- Vol. 8 (2) , 646-661
Open AccessAtom-level descriptors and explainable prediction of iron carbide nanoparticles' cytotoxicity via the Enalos Cloud platform
Iron carbide nanoparticles (ICNPs), a distinct type of magnetic nanostructure, have been proposed as novel candidate therapeutic agents for a wide range of biomedical applications, yet their biocompatibility remains a critical concern for their safe implementation. To mitigate the need for excessive experiments that screen bio-related interactions through conventional pathways, in silico methodologies have been established as cost and time-efficient alternatives. This study presents the development of data-driven workflows for the risk assessment of ICNP-induced cytotoxicity. Two modelling strategies were established: an evidence-based approach relying on experimental features and exposure conditions, and an atomistic-based approach combining attributes that describe NPs at the atomistic scale. While the former methodology struggled to meet the requirements for robust quantitative predictions, the models implemented on the enriched dataset displayed improved accuracy. The resultant Random Forest model fully adheres to the principles outlined by the OECD for the development of quantitative structure–toxicity relationship (QSTR) models. Beyond deciphering the mechanistic influence of individual features, the effect of the selected nanodescriptors was reviewed through Shapley additive values and permutation importance analyses to reveal key input characteristics that drive cell viability predictions. The produced model is disseminated as a free to use web service hosted by the Enalos CHIASMA Cloud Platform (https://www.enaloscloud.novamechanics.com/chiasma/icnp/) and data are publicly available through the NanoPharos database for easy access to the nano-safety community.
- Open Access
- 14 June 2025
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (2) , 1821-1836
Predicting peroxisome proliferator-activated receptor gamma potency of small molecules: a synergistic consensus model and deep learning binding affinity approach powered by Enalos Cloud Platform
Peroxisome proliferator-activated receptor gamma (PPARγ) antagonists play a critical role in regulating glucose and lipid metabolism, making them promising candidates for antidiabetic therapies. To support the ongoing search of such compounds, this study introduces two advanced in silico models for predicting the binding affinity and biological activity of small molecules targeting PPARγ. A neural network was developed to classify compounds as strong or weak binders based on molecular docking scores. Additionally, a consensus model combining Random Forest, Support Vector Machine, and k-Nearest Neighbours algorithms was implemented to predict the antagonistic activity of small molecules. Both models were rigorously validated according to the Organisation for Economic Co-operation and Development (OECD) guidelines, to ensure generalisability and sufficient efficiency in detecting the minority class (active antagonists). Mechanistic insights into how key molecular descriptors influence PPARγ activity were discussed in a posteriori interpretation. A case study involving 34 prioritised per- and polyfluoroalkyl substances (PFAS) were screened with the developed workflows to demonstrate their practical application. The models, integrated into user-friendly web applications via the Enalos Cloud Platform, enable accessible and efficient virtual screening, supporting the discovery of PPARγ modulators.
- 14 June 2025
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (2) , 1821-1836
Open AccessPredicting peroxisome proliferator-activated receptor gamma potency of small molecules: a synergistic consensus model and deep learning binding affinity approach powered by Enalos Cloud Platform
Peroxisome proliferator-activated receptor gamma (PPARγ) antagonists play a critical role in regulating glucose and lipid metabolism, making them promising candidates for antidiabetic therapies. To support the ongoing search of such compounds, this study introduces two advanced in silico models for predicting the binding affinity and biological activity of small molecules targeting PPARγ. A neural network was developed to classify compounds as strong or weak binders based on molecular docking scores. Additionally, a consensus model combining Random Forest, Support Vector Machine, and k-Nearest Neighbours algorithms was implemented to predict the antagonistic activity of small molecules. Both models were rigorously validated according to the Organisation for Economic Co-operation and Development (OECD) guidelines, to ensure generalisability and sufficient efficiency in detecting the minority class (active antagonists). Mechanistic insights into how key molecular descriptors influence PPARγ activity were discussed in a posteriori interpretation. A case study involving 34 prioritised per- and polyfluoroalkyl substances (PFAS) were screened with the developed workflows to demonstrate their practical application. The models, integrated into user-friendly web applications via the Enalos Cloud Platform, enable accessible and efficient virtual screening, supporting the discovery of PPARγ modulators.
- Open Access
- 10 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (10) , 5216
Development of a Robust Read-Across Model for the Prediction of Biological Potency of Novel Peroxisome Proliferator-Activated Receptor Delta Agonists
A robust predictive model was developed using 136 novel peroxisome proliferator-activated receptor delta (PPARδ) agonists, a distinct subtype of lipid-activated transcription factors of the nuclear receptor superfamily that regulate target genes by binding to characteristic sequences of DNA bases. The model employs various structural descriptors and docking calculations and provides predictions of the biological activity of PPARδ agonists, following the criteria of the Organization for Economic Co-operation and Development (OECD) for the development and validation of quantitative structure–activity relationship (QSAR) models. Specifically focused on small molecules, the model facilitates the identification of highly potent and selective PPARδ agonists and offers a read-across concept by providing the chemical neighbours of the compound under study. The model development process was conducted on Isalos Analytics Software (v. 0.1.17) which provides an intuitive environment for machine-learning applications. The final model was released as a user-friendly web tool and can be accessed through the Enalos Cloud platform’s graphical user interface (GUI).
- 10 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (10) , 5216
Open AccessDevelopment of a Robust Read-Across Model for the Prediction of Biological Potency of Novel Peroxisome Proliferator-Activated Receptor Delta Agonists
A robust predictive model was developed using 136 novel peroxisome proliferator-activated receptor delta (PPARδ) agonists, a distinct subtype of lipid-activated transcription factors of the nuclear receptor superfamily that regulate target genes by binding to characteristic sequences of DNA bases. The model employs various structural descriptors and docking calculations and provides predictions of the biological activity of PPARδ agonists, following the criteria of the Organization for Economic Co-operation and Development (OECD) for the development and validation of quantitative structure–activity relationship (QSAR) models. Specifically focused on small molecules, the model facilitates the identification of highly potent and selective PPARδ agonists and offers a read-across concept by providing the chemical neighbours of the compound under study. The model development process was conducted on Isalos Analytics Software (v. 0.1.17) which provides an intuitive environment for machine-learning applications. The final model was released as a user-friendly web tool and can be accessed through the Enalos Cloud platform’s graphical user interface (GUI).
- Open Access
- 23 April 2024
- Published by MDPI AG in Nanomaterials
- Vol. 14 (9) , 734
In Vitro Toxicological Insights from the Biomedical Applications of Iron Carbide Nanoparticles in Tumor Theranostics: A Systematic Review and Meta-Analysis
(1) Background: Despite the encouraging indications regarding the suitability (biocompatibility) of iron carbide nanoparticles (ICNPs) in various biomedical applications, the published evidence of their biosafety is dispersed and relatively sparse. The present review synthesizes the existing nanotoxicological data from in vitro studies relevant to the diagnosis and treatment of cancer. (2) Methods: A systematic review was performed in electronic databases (PubMed, Scopus, and Wiley Online Library) on December 2023, searching for toxicity assessments of ICNPs of different sizes, coatings, and surface modifications investigated in immortalized human and murine cell lines. The risk of bias in the studies was assessed using the ToxRTool for in vitro studies. (3) Results: Among the selected studies (n = 22), cell viability emerged as the most frequently assessed cellular-level toxicity endpoint. The results of the meta-analysis showed that cell models treated with ICNPs had a reduced cell viability (SMD = −2.531; 95% CI: −2.959 to −2.109) compared to untreated samples. A subgroup analysis was performed due to the high magnitude of heterogeneity (I2 = 77.1%), revealing that ICNP concentration and conjugated ligands are the factors that largely influence toxicity (p < 0.001). (4) Conclusions: A dose-dependent cytotoxicity of ICNP exposure was observed, regardless of the health status of the cell, tested organism, and NP size. Inconsistent reporting of ICNP physicochemical properties was noted, which hinders comparability among the studies. A comprehensive exploration of the available in vivo studies is required in future research to assess the safety of ICNPs’ use in bioimaging and cancer treatment.
- 23 April 2024
- Published by MDPI AG in Nanomaterials
- Vol. 14 (9) , 734
Open AccessIn Vitro Toxicological Insights from the Biomedical Applications of Iron Carbide Nanoparticles in Tumor Theranostics: A Systematic Review and Meta-Analysis
(1) Background: Despite the encouraging indications regarding the suitability (biocompatibility) of iron carbide nanoparticles (ICNPs) in various biomedical applications, the published evidence of their biosafety is dispersed and relatively sparse. The present review synthesizes the existing nanotoxicological data from in vitro studies relevant to the diagnosis and treatment of cancer. (2) Methods: A systematic review was performed in electronic databases (PubMed, Scopus, and Wiley Online Library) on December 2023, searching for toxicity assessments of ICNPs of different sizes, coatings, and surface modifications investigated in immortalized human and murine cell lines. The risk of bias in the studies was assessed using the ToxRTool for in vitro studies. (3) Results: Among the selected studies (n = 22), cell viability emerged as the most frequently assessed cellular-level toxicity endpoint. The results of the meta-analysis showed that cell models treated with ICNPs had a reduced cell viability (SMD = −2.531; 95% CI: −2.959 to −2.109) compared to untreated samples. A subgroup analysis was performed due to the high magnitude of heterogeneity (I2 = 77.1%), revealing that ICNP concentration and conjugated ligands are the factors that largely influence toxicity (p < 0.001). (4) Conclusions: A dose-dependent cytotoxicity of ICNP exposure was observed, regardless of the health status of the cell, tested organism, and NP size. Inconsistent reporting of ICNP physicochemical properties was noted, which hinders comparability among the studies. A comprehensive exploration of the available in vivo studies is required in future research to assess the safety of ICNPs’ use in bioimaging and cancer treatment.
- Open Access
- 2 November 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (21) , 15894
Exploring the Binding Effects of Natural Products and Antihypertensive Drugs on SARS-CoV-2: An In Silico Investigation of Main Protease and Spike Protein
In this in silico study, we conducted an in-depth exploration of the potential of natural products and antihypertensive molecules that could serve as inhibitors targeting the key proteins of the SARS-CoV-2 virus: the main protease (Mpro) and the spike (S) protein. By utilizing Induced Fit Docking (IFD), we assessed the binding affinities of the molecules under study to these crucial viral components. To further comprehend the stability and molecular interactions of the “protein-ligand” complexes that derived from docking studies, we performed molecular dynamics (MD) simulations, shedding light on the molecular basis of potential drug candidates for COVID-19 treatment. Moreover, we employed Molecular Mechanics Generalized Born Surface Area (MM-GBSA) calculations on all “protein-ligand” complexes, underscoring the robust binding capabilities of rosmarinic acid, curcumin, and quercetin against Mpro, and salvianolic acid b, rosmarinic acid, and quercetin toward the S protein. Furthermore, in order to expand our search for potent inhibitors, we conducted a structure similarity analysis, using the Enalos Suite, based on the molecules that indicated the most favored results in the in silico studies. The Enalos Suite generated 115 structurally similar compounds to salvianolic acid, rosmarinic acid, and quercetin. These compounds underwent IFD calculations, leading to the identification of two salvianolic acid analogues that exhibited strong binding to all the examined binding sites in both proteins, showcasing their potential as multi-target inhibitors. These findings introduce exciting possibilities for the development of novel therapeutic agents aiming to effectively disrupt the SARS-CoV-2 virus lifecycle.
- 2 November 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (21) , 15894
Open AccessExploring the Binding Effects of Natural Products and Antihypertensive Drugs on SARS-CoV-2: An In Silico Investigation of Main Protease and Spike Protein
In this in silico study, we conducted an in-depth exploration of the potential of natural products and antihypertensive molecules that could serve as inhibitors targeting the key proteins of the SARS-CoV-2 virus: the main protease (Mpro) and the spike (S) protein. By utilizing Induced Fit Docking (IFD), we assessed the binding affinities of the molecules under study to these crucial viral components. To further comprehend the stability and molecular interactions of the “protein-ligand” complexes that derived from docking studies, we performed molecular dynamics (MD) simulations, shedding light on the molecular basis of potential drug candidates for COVID-19 treatment. Moreover, we employed Molecular Mechanics Generalized Born Surface Area (MM-GBSA) calculations on all “protein-ligand” complexes, underscoring the robust binding capabilities of rosmarinic acid, curcumin, and quercetin against Mpro, and salvianolic acid b, rosmarinic acid, and quercetin toward the S protein. Furthermore, in order to expand our search for potent inhibitors, we conducted a structure similarity analysis, using the Enalos Suite, based on the molecules that indicated the most favored results in the in silico studies. The Enalos Suite generated 115 structurally similar compounds to salvianolic acid, rosmarinic acid, and quercetin. These compounds underwent IFD calculations, leading to the identification of two salvianolic acid analogues that exhibited strong binding to all the examined binding sites in both proteins, showcasing their potential as multi-target inhibitors. These findings introduce exciting possibilities for the development of novel therapeutic agents aiming to effectively disrupt the SARS-CoV-2 virus lifecycle.